Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

Christensen, Tine Nøhr; Andersen, Per Kragh; Langer, Seppo W.; Fischer, Barbara

doi:10.3390/diagnostics11020174

Cited by 11 publications

(10 citation statements)

References 61 publications

(158 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, six meta-analyses containing information on the prognostic value of PET with different radiopharmaceuticals in patients with NETs and NECs were included (Table 2) [8,12,17,20,27,41]. These evidence-based manuscripts provided quantitative data about the prognostic value of 68 Ga-SSA PET or 18 F-FDG PET in patients with thoracic and/or gastroenteropancreatic NETs [8,17,20] or SCLC [12,27,41] in terms of disease control rate (DCR), event-free survival (EFS), progression-free survival (PFS) or overall survival (OS).…”

Section: Prognostic Value Of Pet With Different Radiopharmaceuticals In Neuroendocrine Neoplasmmentioning

confidence: 99%

“…Three different meta-analyses clearly demonstrated that 18 F-FDG PET has a significant prognostic value in patients with SCLC, in particular taking into account metabolic parameters at PET such as SUVmax of the primary lesion, metabolic tumor volume (MTV) or total lesion glycolysis (TLG) [12,27,41]. Higher values of these metabolic parameters were associated with a poorer prognosis regarding EFS, PFS and OS [12,27,41].…”

Section: Small Cell Lung Cancer (Sclc)mentioning

confidence: 99%

See 1 more Smart Citation

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

Treglia

Sadeghi

Giovinazzo

et al. 2021

Cancers

View full text Add to dashboard Cite

Background: Several meta-analyses have reported quantitative data about the diagnostic performance, the prognostic value, the impact on management and the safety of positron emission tomography (PET) including related hybrid modalities (PET/CT or PET/MRI) using different radiopharmaceuticals in patients with neuroendocrine neoplasms. We performed an umbrella review of published meta-analyses to provide an evidence-based summary. Methods: A comprehensive literature search of meta-analyses listed in PubMed/MEDLINE and Cochrane Library databases was carried out (last search date: 30 June 2021). Results: Thirty-four published meta-analyses were selected and summarized. About the diagnostic performance: 68Ga-SSA PET yields high diagnostic performance in patients with NETs and PGL; 18F-FDOPA PET yields good diagnostic performance in patients with intestinal NETs, PGL, NB, being the best available PET method in detecting rMTC; 68Ga-exendin-4 PET has good diagnostic accuracy in detecting insulinomas; 18F-FDG PET has good diagnostic performance in detecting aggressive neuroendocrine neoplasms. About the prognostic value: 68Ga-SSA PET has a recognized prognostic value in well-differentiated NETs, whereas 18F-FDG PET has a recognized prognostic value in aggressive neuroendocrine neoplasms. A significant clinical impact of 68Ga-SSA PET and related hybrid modalities in patients with NETs was demonstrated. There are no major toxicities or safety issues related to the use of PET radiopharmaceuticals in patients with neuroendocrine neoplasms. Conclusions: Evidence-based data support the use of PET with different radiopharmaceuticals in patients with neuroendocrine neoplasms with specific indications for each radiopharmaceutical.

show abstract

Section: Prognostic Value Of Pet With Different Radiopharmaceuticals In Neuroendocrine Neoplasmmentioning

confidence: 99%

Section: Small Cell Lung Cancer (Sclc)mentioning

confidence: 99%

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

Treglia

Sadeghi

Giovinazzo

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Changes in metabolic activity can be measured in vivo via metabolomics, magnetic resonance spectroscopy, PET, and stable isotope tracing [ 32 ]. In particular, 18-F-FDG PET-CT is not only used to diagnose malignant tumors of different cancers, but also reflects treatment response [ 33 ], while parameters such as SUV max , metabolic tumor volume, and total lesion glycolysis are associated with the prognosis of patients with cancer [ 10 , 11 , 12 , 13 , 14 , 34 ]. Previous findings suggest that the uptake of 18F-FDG has an independent prognostic value in patients newly diagnosed with NSCLC [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Relationship between Systemic Inflammatory Markers, GLUT1 Expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-Small Cell Lung Carcinoma and Their Prognostic Significance

et al. 2023

View full text Add to dashboard Cite

Background: Factors involved in inflammation and cancer interact in various ways with each other, and biomarkers of systemic inflammation may have a prognostic value in cancer. Glucose transporter 1 (GLUT1) plays a pivotal role in glucose transport and metabolism and it is aberrantly expressed in various cancer types. We evaluated the differential expression of GLUT1, along with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in non-small-cell lung cancer (NSCLC), and then analyzed their prognostic significance. Methods: A total of 163 patients with resectable NSCLC were included in this study. Tumor sections were immunohistochemically stained for GLUT1 and GLUT3. Maximum standardized uptake value (SUVmax) was measured by preoperative FDG-PET, and neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), and lymphocyte–monocyte ratio (LMR) were derived from pretreatment blood count. Results: GLUT1 and GLUT3 was positively expressed in 74.8% and 6.1% of the NSCLC tissues, respectively. GLUT1 expression was significantly correlated with squamous cell carcinoma histology, poor differentiation, high pathologic stage, old age, male, smoking, and high SUVmax (>7) (all p < 0.05). The squamous cell carcinoma and smoker group also showed significantly higher SUVmax (both p < 0.001). Systemic inflammation markers, including NLR, PLR, and LMR, were positively correlated with high SUVmax (all p < 0.05). High GLUT1 expression, high SUVmax, high NLR, and low LMR, were significantly associated with poor overall survival in patients with NSCLC. However, in the multivariate survival analysis, LMR was an independent prognostic factor overall (HR 1.86, 95% CI 1.05–3.3) and for the stage I/II cohort (HR 2.3, 95% CI 1.24–4.3) (all p < 0.05). Conclusions: Systemic inflammatory markers—NLR, PLR, and LMR are strongly correlated with the SUVmax and are indicators of aggressive tumor behavior. Specifically, LMR is a promising prognostic biomarker in NSCLC patients.

show abstract

“…On the other hand, higher [ 18 F]FDG uptake was associated with worse EFS and OS [ 69 ]. Furthermore, the association between higher values of [ 18 F]FDG quantitative parameters (such as [ 18 F]FDG SUVmax of the primary lesion, metabolic tumor volume, total lesion glycolysis) and inferior EFS, PFS, and OS was demonstrated [ 70 ].…”

Section: Imaging Of Nens With Radiolabeled Somatostatin Analoguesmentioning

confidence: 99%

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

Ambrosini

Zanoni

Filice

et al. 2022

Cancers

View full text Add to dashboard Cite

Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors that require multidisciplinary discussion for optimal care. The theranostic approach (DOTA peptides labelled with [68Ga] for diagnosis and with 90Y or 177Lu for therapy) plays a crucial role in the management of NENs to assess disease extension and as a criteria for peptide receptor radionuclide therapy (PRRT) eligibility based on somatostatin receptor (SSTR) expression. On the diagnostic side, [68Ga]Ga-DOTA peptides PET/CT (SSTR PET/CT) is the gold standard for imaging well-differentiated SSTR-expressing neuroendocrine tumors (NETs). [18F]FDG PET/CT is useful in higher grade NENs (NET G2 with Ki-67 > 10% and NET G3; NEC) for more accurate disease characterization and prognostication. Promising emerging radiopharmaceuticals include somatostatin analogues labelled with 18F (to overcome the limits imposed by 68Ga), and SSTR antagonists (for both diagnosis and therapy). On the therapeutic side, the evidence gathered over the past two decades indicates that PRRT is to be considered as an effective and safe treatment option for SSTR-expressing NETs, and is currently included in the therapeutic algorithms of the main scientific societies. The positioning of PRRT in the treatment sequence, as well as treatment personalization (e.g., tailored dosimetry, re-treatment, selection criteria, and combination with other alternative treatment options), is warranted in order to improve its efficacy while reducing toxicity. Although very preliminary (being mostly hampered by lack of methodological standardization, especially regarding feature selection/extraction) and often including small patient cohorts, radiomic studies in NETs are also presented. To date, the implementation of radiomics in clinical practice is still unclear. The purpose of this review is to offer an overview of radiolabeled SSTR analogues for theranostic use in NENs.

show abstract

Prognostic Value of 18F–FDG–PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature

Cited by 11 publications

References 61 publications

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

Relationship between Systemic Inflammatory Markers, GLUT1 Expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-Small Cell Lung Carcinoma and Their Prognostic Significance

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

Contact Info

Product

Resources

About